Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Accumulated Expenses (2018 - 2025)

Viemed Healthcare's Accumulated Expenses history spans 8 years, with the latest figure at $23.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 18.62% year-over-year to $23.9 million; the TTM value through Dec 2025 reached $23.9 million, up 18.62%, while the annual FY2025 figure was $23.9 million, 18.62% up from the prior year.
  • Accumulated Expenses reached $23.9 million in Q4 2025 per VMD's latest filing, down from $25.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $25.0 million in Q3 2025 to a low of $8.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $14.9 million, with a median of $14.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: plummeted 35.54% in 2021, then skyrocketed 75.05% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $8.9 million in 2021, then grew by 24.98% to $11.1 million in 2022, then skyrocketed by 58.47% to $17.6 million in 2023, then rose by 14.67% to $20.2 million in 2024, then increased by 18.62% to $23.9 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Accumulated Expenses are $23.9 million (Q4 2025), $25.0 million (Q3 2025), and $18.6 million (Q2 2025).